NCT05955521View on ClinicalTrials.gov

Exosome as the Prognostic and Predictive Biomarker in EBC Patients

NAActive, not recruitingINTERVENTIONAL
Enrollment

200

Participants

Timeline

Start Date

May 1, 2021

Primary Completion Date

July 1, 2023

Study Completion Date

July 1, 2028

Conditions
Triple Negative Breast CancerHER2-positive Breast Cancer
Interventions
PROCEDURE

exosome and ctDNA evaluation

Serial exosome and ctDNA evaluation during follow up period between neoadjuvant chemotherapy and surveillance after curative surgery.

Trial Locations (1)

06351

Ji-Yeon Kim, Seoul

All Listed Sponsors
lead

Samsung Medical Center

OTHER